Verified peer comparison

TMO vs JNJ

Thermo Fisher Scientific Inc. compared with Johnson & Johnson. This page compares both source-verified company profiles and does not introduce an unverified price target.

TMO

Thermo Fisher Scientific Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

JNJ

Johnson & Johnson

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

TMO: Life Sciences Tools and Services

JNJ: Pharmaceuticals

Upside lens

TMO: Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services. The completed Clario acquisition expands Thermo Fisher's clinical research capabilities and creates cross-selling and productivity opportunities within biopharma services. Continued productivity initiatives can support margin expansion even while end-market recovery remains uneven.

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Risk lens

TMO: Muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand. Slightly declining China revenue and uncertain local funding conditions could delay a broader recovery in Asia-Pacific demand. Debt increased following acquisition activity, raising integration, financing-cost, and capital-allocation risk if expected returns take longer to emerge.

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

Verified sources

Thermo Fisher Scientific Reports First Quarter 2026 ResultsThermo Fisher Scientific Inc. · earningsVerified